WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 12, 21-42. Review Article ISSN 2277–7105

MRNA-BASED VACCINES IN MELANOMA THERAPY: MECHANISMS, ADVANCES, AND CLINICAL PERSPECTIVES

***Saher N. Kazi, Prof. Trupti V. Kadam, Prof. (Dr.) Avinash B. Darekar**

K. V. N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education & Research, Canada Corner, Nashik, 422002, Maharashtra, India.

Article Received on 16 May 2026,
Article Revised on 05 June 2026,
Article Published on 16 June 2026,

https://doi.org/10.5281/zenodo.20678691

***Corresponding Author**
Saher N. Kazi
K. V. N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education & Research, Canada Corner, Nashik, 422002, Maharashtra, India.

How to cite this Article: *Saher N. Kazi, Prof. Trupti V. Kadam, Prof. (Dr.) Avinash B. Darekar. (2026). Mrna-Based Vaccines In Melanoma Therapy: Mechanisms, Advances, And Clinical Perspectives. World Journal of Pharmaceutical Research, 15(12), 21–42.

ABSTRACT

Melanoma is an aggressive type of skin cancer that has high metastatic ability and resists standard therapies such as radiotherapy, chemotherapy, and targeted therapy. Although, signific ant advancements have been achieved in the evolving field of immunotherapy especially immune checkpoint inhibitors; several hurdles including heterogeneous response and treatment resistance are still challenging for chronic diseases. In this context, mRNA-based vaccines represent an innovative and promising approach to melanoma therapy. Herein, we review how melanomagenesis is understood at the biological level including origins (and genetic mutations: BRAF, NRAS); tumor microenvironment; and mechanisms of immune evasion. It also focuses more on the principles of mRNA vaccine technology, including types of vaccines and structural components and delivery systems (lipid nanoparticles, etc. This includes an overview of the mechanism of action of mRNA vaccines and their ability to mount robust cellular and humoral immune responses by presentation of antigens with T-cell activation. The review also discusses melanoma mRNA vaccines including tumor-associated antigens and personalized neoantigens. Considering clinical advances, innovative approaches like early-phase trial designs and combinations with immune checkpoint inhibitors are discussed for their promising safety effective potential. The report covers advantages of mRNA vaccines, e.g., fast production, specificity to the antigen and personalization potential; it also addresses major challenges such as stability/delivery efficiency/cost. Future directions will ultimately

emphasize the promise of AI/augmented delivery systems, and wider applications across a number of cancers. Ultimately, mRNA vaccines represent a groundbreaking strategy for melanoma treatment with remarkable capacity to improve therapeutic results for patients and reshape oncology immunotherapeutics.

KEYWORDS: mRNA vaccines, Melanoma, Cancer immunotherapy, Neoantigens.

INTRODUCTION

Melanoma, due to malignant transformation of melanocytes, is one of the most aggressive and deadliest types of skin cancer. Melanoma has been identified as a major public health issue in recent decades, with rising rates of melanoma globally. Epidemiological data indicate that melanoma incidence has risen more steeply than almost any other cancer type, particularly among fair-skinned populations across North America and in European, Australian and New Zealand countries.[1,2,3,4]

Currently, melanoma contributes substantially to global cancer incidence and mortality, with increasing trends expected in the coming decades.[3] There are significant geographic, ethnic, and so on disparities of the disease[4] which correlate a higher incidence rate with prevalence to ultraviolet (UV) radiation exposure and lower melanin defence.

Although melanoma makes up only a minor part (less than 5%) of all skin cancers, it accounts for the majority of skin cancerrelated deaths due to high metastatic potential and aggressiveness of this disease.[1,2] Melanoma is also one of the most common cancers among young adults and a leading cause of global morbidity and mortalit.[4]

1. Limitations of Conventional Therapies

1.1 Chemotherapy

Caution: The use of conventional chemotherapy in the treatment of melanoma has been well known for dew decades, however, its clinical activity is limited. Notovan B[18] Melanoma has intrinsic resistance to most chemotherapeutic agents due to up-regulated DNA repair mechanism, heterogeneity of tumor and drug resistance mechanisms. Consequently, chemotherapy often produces low response rates and minimal survival benefit in advanced melanoma patients.[5,6]

1.2 Radiotherapy

In melanoma radiotherapy is almost exclusively an adjuvant and palliative option for the treatment of metastatic lesions. However, melanoma cells are inherently radiosensitive and therefore radiotherapy has limited effectiveness as a curative treatment. Though it provides some local tumor control, the impact on overall survival is modest.[5]

1.3 Targeted Therapy

Targeted therapies specifically guided by BRAF/MEK alterations have translates into dramatic improvement of clinical outcomes among an enriched patient population with such mutations. These approaches often result in the emergence of rapid resistance and subsequent disease progression. Additionally, their long-term efficacy is still compromised by side-effects and tumor recurrence.[6]

1.4 Emergence of Immunotherapy

An insight into the emergence of immunotherapy as a transformative modality for treatment of melanoma can be derived from an exploration of the limitations endured when conventional therapies are attempted. The introduction of immune checkpoint inhibitors directed against programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have resulted in remarkable increases in survival of patients with metastatic disease and durable responses.[7,8,9]

These advances are impactful, but many patients fail to respond to immunotherapy and some experience immune-related adverse effects. The existence of diverse mechanisms of resistance and variable response between patients reveals the need for better, more tailored approaches, particularly in immunotherapy.[9]

Rationale for mRNA-Based Vaccines in Melanoma

mRNA-; based vaccines have emerged as a novel and attractive approach to cancer immunotherapy, including melanoma. These vaccines function by delivering mRNA that encodes tumor specific antigens to host cells in the whose context antigen expression and adaptive immunity is provoked. Entereinto vaccine cancer vaccine the rapid development capability of mRNA technology has also expedited applications in oncology divisions.[10,11,12]
Melanoma having a high tumoral mutational burden allows for the selection of tumor-specific neoantigens, thus lending itself to personalized vaccine approaches. Personalized mRNA

vaccines can be designed with tumor-specific antigens in mind for enhanced specificity and potent immune response.[11]

In addition, mRNA vaccines have demonstrated strong $CD8^+$ cytotoxic T-cells and $CD4^+$ helper T-cell responses that are critical for robust anti-tumor immunity. Particularly incentive results have been derived from ongoing clinical trials developed on mRNA vaccines in the aspect of safety and immunogenicity and therapeutic potential, supporting the emergence of mRNA vaccine as a next-generation strategy to treat melanoma.[10,13,14]

2. Biology and Pathogenesis of Melanoma

2.1 Origin of Melanoma (Melanocytes)

Melanoma originates from melanocytes, pigment-producing cells of neural crest origin located in the basal layer of the epidermis. They synthesize melanin, one of the factors responsible for protecting the skin from damage due to UVA (Ultraviolet A) rays. Long term exposure to ultraviolet (UV) radiation causes damage to the DNA in melanocytes leading to genomically disruptive cells capable of undergoing a malignant transformation.[1,2]

Melanoma progression describes the multistep evolution that underlie the acquisition of a more aggressive nature by tumors, beginning with benign melanocytic nevi and evolving towards dysplastic nevi and eventually invasive melanoma. It is the cumulative genetic and environmental influences that result in this transition, driven by UV exposure, oxidative stress propensity and individual predisposition.[4]

2.2 Genetic Mutations (BRAF, NRAS)

Genetic alterations are a hallmark of melanoma pathogenesis, particularly mutations identified within prominent oncogenes that causally drive the unrestrained proliferation and survival of cells. The most common mutations are BRAF mutations, which occur in 40–60% of melanoma. In non-embryonic cells, the BRAF V600E mutation results in persistent activation of the MAPK/ERK pathway that drives tumor growth and progression.[4,15]

Mutation of the NRAS gene is also common (approximately 15–20% of melanomas). Mall chromosomal aberrations associated with mutated NRAS also included activation of the MAPK and PI3K pathways, which are shared by cell proliferation, survival and metastasis.[15,16]

These mutations are frequently mutually exclusive and constitute critical therapeutics targets. However, acquired resistance to targeted therapy remains a critical clinical barrier.[16]

2.3 Tumor Microenvironment

Introduction t TME is an important component in melanoma progression and therapy response. It is created through a molecular web of cancer cells, stromal cells, immune cells, blood vessels and matrix molecules. Interactions of melanoma cells with their microenvironment drive tumor growth, angiogenesis and metastasis.[6]

T lymphocytes, dendritic cells, macrophages and Tregs are either inhibited from or promote tumor progression depending on their functional availability in the TME. To establish an immunosuppressive milieu that facilitates tumor immune escape, TAMs (tumor-associated macrophages) and regulatory T cells (Tregs) are recruited under normal circumstances.[6,17]

Along with cytokines, chemokines, and growth factors they autonomously secrete in the TME or elicit surrounding cells to modulate tumor behavior and therapy response.[17]

2.4 Immune Evasion Mechanisms

There are various mechanisms employed by melanoma to escape immune surveillance. One of the main mechanisms involves the upregulation of immune checkpoints such as programmed death-ligand 1 (PD-L1), which binds to PD-1 receptors on T cells and stops them from killing.[9]

Immune evasion: Melanoma cells also downregulate major histocompatibility complex (MHC) molecules, and thus reduce antigen presentation to immune cells.[9,18] Inhibition of potent anti-tumor immune response is additionally reinforced through the secretion of immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β).[18]

Mechanistically those would be linked to some recruitment of immunosuppressive cells already known (Tregs, myeloid-derived suppressor cells [MDSCs] etc), as well metabolic changes that were happening in the tumor microenvironment which compromises T-cells viability.[17,18] These immune escape mechanisms are crucial for tumor progression and the acquisition of therapy resistance.

3. mRNA Vaccine Technology

3.1 Types of mRNA Vaccines

Note: mRNA vaccines are a new type of therapeutic agents which deliver synthetic messenger RNA encoding the sequence of an antigen enabling host cells to transcribe and translate proteins that can induce immune responses. There are two classes of mRNA vaccines—self-amplifying mRNA vaccines and non-replicating RNA that are primarily classified according to their designs and functional characteristics.[10,11]

3.1.1 Non-replicating mRNA

Non-replicating mRNA vaccines consist of single-stranded mRNA molecule encoding for the antigen of interest, and elements required for translation. Once released in the cytoplasm, the mRNA is translated into a target antigen, which is further processed and presented by antigen-presenting cells, resulting an immune response.[10]

These vaccines are relatively straightforward in design and have seen broad use in clinical practice due to their safety profile and ease of production. But, because of their comparatively short half-life and the limited expression of protein induced, high doses or repeated administration may be required to achieve optimal immunogenicity in the host.[11]



Figure 1: Schematic representation of non-replicating and self-amplifying mRNA vaccines.

3.1.2 Self-amplifying mRNA (saRNA)

Self-amplifying mRNA vaccines comprise viral replicon vectors with additional RNA genetic elements encoding the RNA-dependent RNA polymerase. This facilitates intracellular mRNA amplification, resulting in higher antigen expression from lower initial doses.[12]

The key idea is that saRNA has the capacity to replicate, which represents a significant advantage over non-replicating mRNA vaccines: because as each replicative cycle will generate more antigen than several rounds of translation. Hence an enhanced immune response due to multiple copies of antigen being produced. Their increased size and complexity can hinder delivery and stability.[12,19]

3.2 Structural Domains of mRNA Vaccines

The stability and effectiveness of mRNA vaccines are determined by their structural design, which is composed of the following important components.[12,13]

3.2.1 5′ Cap

The 5′ cap structure is an important regulator of mRNA stability and for the efficient translation. This protects mRNA from exonuclease degradation and helps with ribosomal recognition which ultimately enhances translation (protein synthesis).[19]

3.2.2 Untranslated Regions (UTRs)

The 5′ and 3′ untranslated regions (UTRs) participate in a wide range of regulatory processes including mRNA stability, localization, and translation efficiency. Utilizing optimized UTR sequences can significantly improve antigen expression.[20]

3.2.3 Open Reading Frame (ORF)

Yields an ORF that encodes the antigenic protein of interest. Codon optimization of the ORF is a common method used to increase rates of translation and levels of protein expression.[20]

3.2.4 Poly(A) Tail

Because it protects mRNA from degradation and promotes its interaction with translation machinery, the polyadenylated tail at the 3′ end [or downstream of transcription start site] is helpful in mRNA stability and translation efficiency.[19]



Figure 2: Structural components of mRNA vaccines including 5′ cap, UTRs, ORF, and poly(A) tail.

3.3 mRNA Vaccines Delivery Systems

One reason naked mRNA-based vaccines have sluggish development is the inefficient delivery of mRNA to target cells, which, particularly in the case of naked mRNA, is rapidly degraded by nucleases. Various delivery systems have been designed to enhance their stability and cellular internalization.

3.3.1 Lipid Nanoparticles (LNPs)

Lipid nanoparticles (LNPs) are the most standard delivery technology for mRNA vaccines LNPs encapsulate mRNA payloads to protect them from proteolytic enzymes and can help facilitate endocytosis mediated cell delivery of the payload. The LNPs also promote endosomal escape, allowing mRNA to be released into the cytosol for translation thereafter.[21,22]

In addition, LNPs have demonstrated adjuvant properties to enhance immune responses. It is those in our view that have demonstrated efficacy via a number of distinct mRNA delivery vehicles and hence are the broadest clinical utility approach.[12]

3.3.2 Polymer-Based Delivery Systems

One class of polymer-based delivery system for mRNA transfection investigated includes cationic polymers, such as poly (ethylene imine) (PEI). These systems form complexes with negatively charged mRNA which facilitate their cellular uptake and provide protection from degradation.[23]

Polymeric systems have advantages of tunability and stability, but have made less clinical progress owing to higher toxicity and lower transfection efficiencies compared with lipid nanoparticles.[23]

4. Mechanism of action

Fundamentally, mRNA vaccines are defined as the delivery of synthetic mRNA encoding for specific tumor associated antigens into host cells leading to expression of the antigen and the development of adaptive immune response. They replicate natural viral infection and therefore enhance both humoral- and cell-mediated immunity.[10,11]



Figure 3: Overall mechanism of action of mRNA vaccines showing cellular uptake, antigen expression, and immune activation.

4.1 Cellular Uptake of mRNA

Since mRNA vaccines are mostly delivered via lipid nanoparticles (LNP [[7]]), they utilize endocytosis immediately after foundation, to internalize host' cells. These nanoparticles help protect mRNA from degradation outside of cells and promote the uptake of the particle containing mRNA by antigen-presenting cell for example dendritic cell.[21,22]

Subsequently, mRNA must be released into the cytoplasm from endosomes generated through internalization to enable translation and protein synthesis. Escape from the endosome is essential, and a critical step that enhances vaccine potency.[21]

4.2 Translation into Antigen Protein

Once released into the cytoplasm, mRNA is sensed and translated by endogenous host ribosomal networks to produce the encoded antigenic protein. This occurs much in the same way that endogenous mRNA translation operates, permitting protein synthesis to be accelerated in the absence of genome integration.[10,20]

Post translational modification of the expressed antigen and subsequent presentation to immune recognition In addition, mRNA possesses stability which permits an improvement the expression of antigen and reduced long-term safety concerns.[11]

4.3 Pathogen Antigen Presentation by MHC Class I and II:

This leads to the gain of MHC molecules on the cell surface and the further processing of this synthesized antigen. Cytoplasmic-synthesized antigens will be presented on MHC class I motifs that are acknowledged by CAR $CD8^+$ T cells while an antigen from the extracellular break or cross introduced will encounter with antigen handling in MHC class II form rather recognized to particular CAR $CD4^+$ T cell.[12]

This bidirectional highway of presentation serves to engage both cytotoxic and helper T-cells, resulting in strong anti-tumor immunity.[24,25]

4.4 Activation of T Cells

• $CD8^+$ Cytotoxic T Cells

This critical information is conveyed to T-cells via antigen presentation through the MHC class I molecules and culminates in activation of $CD8^+$ cytotoxic T lymphocytes (CTLs). They mediate anti-tumor immunity due to direct recognition of target antigen-expressing tumor cells and resultant lysis via release of perforin and granzyme.[25]

• $CD4^+$ Helper T Cells

On the other hand, MHC class II presented Antigen-derived peptides can activate $CD4^+$ helper T cells. They are crucial in directing immune responses by releasing cytokines that activate cytotoxic T cells, B cell differentiation and other effector functions of the immune system.[24,25]

In addition to teaching the tTME and directing tumor cell killing, $CD4^+$ T cells contribute to memory formation, which is an important component for durable therapeutic effect against tumor recurrence.[25]

4.5 Induction of Anti-tumoral Immune Response

Simultaneous activation of $CD8^+$ and $CD4^+$ T cells at the distal end creates a potent and synchronized immune bombardment on tumor cells. After activation, these cytotoxic T cells move into the tumor microenvironment and can kill neoplastic cells expressing the specific target antigen.

Apart from adaptive immunity, both innate immune responses get directed to mRNA vaccines through PRR (pattern recognition receptor) activation which further paces the leading inducing strong adaptive immunity.[23] Immunological memory generation will ensure continued vigilance against tumor relapses, hence mRNA vaccines may represent a potential long-term strategy for cancer control.[10,23]

5. mRNA Vaccines in Melanoma Therapy

Recently, tumor antigen mRNA-based vaccines have become an attractive immunologic approach for melanoma by enabling efficient and specific generation of anti-tumor immune response. These vaccines are capable of encoding tumor-associated antigens (TAAs) or recruiting patient-specific neoantigens, providing an example of enhancing immune recognition solely to malignant melanoma cells.[10,11]

5.1 Tumor-Associated Antigens (TAAs)

Tumor-associated antigens are proteins that melanoma cells express and which the immune system can recognize. mRNA vaccines based on many well-defined TAAs have been extensively investigated as therapeutic targets.

• MART-1 (Melanoma Antigen Recognized by T cells-1):

MART-1 is a melanocyte differentiation antigen that is transiently expressed by the majority of melanoma cells. It's partaken in melanosome formation and very immunogenic, therefore a good target for cancer vaccines. The MART-1-derived peptides are displayed on MHC class I molecules and recognized by $CD8^+$ T cells, leading to the killing of tumor cells.[26]

• gp100 (Glycoprotein 100)

One such melanocyte lineage-specific antigen is gp100, another protein associated with melanin synthesis. It has been extensively studied for melanoma immunotherapy and elicits strong cytotoxic T-cell response. Immune checkpoint inhibitors have been especially

beneficial after vaccination of gp100 based vaccines and stimulating the anti-tumor immunity.[27]

• Tyrosinase

Tyrosinase is a rate-limiting enzyme in the melanin biosynthetic pathway, which is upregulated in melanoma cells. Another key target antigen of immune-based therapies. Tyrosinase-derived epitopes can prime both $CD8^+$ and $CD4^+$ T-cell responses, contributing to the recognition and destruction of tumor cells.[26,27]

5.2 Personalized Neoantigen Vaccines

• Concept of Individualized Vaccines

Unlike tumor-associated antigens, neoantigens are encoded by mutation events that cause the development of tumors and do not exist in healthy tissues. That makes them highly accurate targets, with very little chance of off-target effects. Personalized mRNA vaccines are tailor-made according to an individual's tumor mutational profile, eliciting a unique immune response.[10,13]

These vaccines generate many neoantigens that enable the immune system to recognize and eliminate heterogeneous populations of tumor cells. To improve therapeutic efficacy, limiting the potential for immune escape.[10]

• Tumor Sequencing Approach

Personalized neoantigen vaccines are created by performing NGS on tumor DNA and RNA to seek somatic mutations. Bioinformatics tools have then been used for predicting non-synonymous mutation in immunogenic neoantigens capable of binding the major histocompatibility complex (MHC) molecules.

Selected neoantigens are subsequently encoded into mRNA constructs and formulated into vaccines for administration. Such an approach allows rapid and precise design of patient-specific therapies, representing an enormous leap for precision oncology.[14]

5.3 Key Vaccine Candidates

• mRNA-4157

mRNA-4157, a personalized neoantigen-based mRNA vaccine product for melanoma. It encodes multiple patient-specific neoantigens and is engineered to induce robust T-cell-mediated immunity.

Patients with high-risk mRNA-4157/melanoma who received the agent had recurrence-free survival compared to treatments, particularly immune checkpoint inhibitors (e.g., pembrolizumab)[28] in Phase 2 trials. These results reinforce its potential as a next-generation cancer vaccine.

• Other Experimental mRNA Vaccines

Other melanoma mRNA vaccines under investigation include experimental ones. These include vaccines that encode shared tumor-associated antigens as well as personalized neoantigen.

Early-phase clinical trials have demonstrated the general tolerability of such vaccines, and their ability to induce strong antigen-specific immune responses. Additionally, combinations with checkpoint inhibitors and other immunotherapies have also been explored to enhance therapeutic outcomes.[11,14]

6. Clinical Advances and Trials

There has been rapid translation of mRNA-based vaccines from preclinical studies to clinical testing in melanoma, where there are promising safety data, immunogenicity and evidence for therapeutic activity. Numerous early-phase clinical trials and combinatorial approaches highlight them as relevant mediators of contemporary cancer immunotherapy.[6,9]

6.1 Early-Phase Trials (Phase I/II)

• Safety and Immunogenicity

Previous mRNA vaccines clinical trials on melanoma phase I and II were performed focused mainly on safety, tolerability, and immunogenicity. These studies have consistently demonstrated that mRNA vaccines are well tolerated on the whole, with most adverse events being mild to moderate: local reactions at the site of injection; fatigue and fair flu-like symptoms1.

Perhaps most importantly, early clinical studies show that mRNA vaccines induce strong antigen-specific immune responses. Personalized neoantigen mRNA vaccines have been shown to elicit strong $CD4^+$ and $CD8^+$ T-cell responses, both of which are necessary for adequate anti-tumor efficacy.[13,14]

In example, work demonstrated with targeted neoantigen vaccines revealed that patients elicited durable T-cell responses to multiple tumour-derived antigens in the wake of vaccination, suggesting this approach is viable in melanoma.[4,12]

6.2 Combination Therapies

• mRNA Vaccines + Immune Checkpoint Inhibitors

Combination of mRNA vaccines with immune checkpoint inhibitors to enhance therapeutic efficacy. The combination strategy here seeks to elicit tumor-specific immune responses (via vaccines) and overcome immune suppression (via checkpoint blockade).[10,11]

Checkpoint inhibitors that target PD-1/PD-L1 pathways have the ability to enhance T-cell activity via immune exhaustion blockade, thus further sustaining an immune response induced by the vaccine.[9]

• Example: Pembrolizumab

PD-1 inhibitors combinations with mRNA vaccines has been extensively exploited, among which Pembrolizumab was the most explored. Although pembrolizumab together with personalized mRNA vaccines (e.g., mRNA-4157) strongly enhance immune responses and reduce disease recurrence, as proven in melanoma patients in clinical trials.[28]

The latter additive effect has been attributed to enhanced tumor-reactive T cell mobilization and retention resulting in increased anti-tumor immune responses.[9,28]

6.3 Clinical Outcomes

• Response Rates

Preclinical studies of mRNA vaccines for use in melanoma have shown encouraging response rates, particularly when combined with checkpoint inhibitors. Patients receiving personalized mRNA vaccines have been reported to demonstrate increased tumor-specific immune responses, and in some cases objective tumor regression.[13,28]

Furthermore, combination therapies are observed to improve response rates compared to monotherapy indicating the potential benefit of integrating mRNA vaccines into existing immunotherapeutic regimens.[28]

• Survival Benefits

Novavax is another newer generation of vaccine, however newly emerging clinical data suggests that mRNA vaccination can increase survival rates in melanoma patients. Proof-of-concept therapies for mRNA blockade in patients with malignancies has demonstrated improved recurrence-free survival and reduced risk of disease progression.[28]

Such lasting immunological memory generated by mRNA vaccines can also protect from tumor relapses and represents a landmark advantage of these therapies compared with classical ones.[10,29]

Data on duration of follow-up are still being accrued but the available data suggest that mRNA vaccines may represent an important component of melanoma therapeutic modalities.[10,11]

7. Advantages of mRNA Vaccines

Compared to classical vaccine platforms and available cancer immunotherapies, mRNA-based vaccines display several advantages which position them as strong candidates for melanoma therapy. These properties enable rapid development, high specificity and strong potential for immunogenicity.[10,11]

7.1 Rapid Design and Production

One of the most potent features has been the capability to rapidly design and manufacture mRNA vaccines. Instead, the mRNA vaccines can be created through in vitro transcription methods that allow for rapid and scalable production compared to conventional vaccines, which involve cell culture or protein synthesis.[10]

This benefits access, enabling evasion of immune responses while providing a rapid response to newly emerging targets such as tumor-specific mutations present in melanoma. The duration from antigen discovery to vaccine production can be drastically shortened, which is particularly valuable for personalized cancer vaccines.[11,12]

7.2 High Specificity

This unique feature of mRNA vaccines allows for the engineering of mRNA that encodes an antigen (e.g., a specific tumor-associated antigen or even patient-specific neoantigens), which can selectively target malignant cells and spare normal tissues. The high specificity of this method improves efficacy and reduces off-target effects.[10,13]

In melanoma, because of its high mutational burden, mRNA vaccines can target many neoantigens in parallel and therefore are able to tackle tumor heterogeneity and boost immune recognition.[13,14]

7.3 Non-Infectious and Safe

The administered mRNA vaccines are non-infectious and without a capability for integration into the host genome thereby preventing any risk of insertional mutagenesis. Furthermore, the mRNA is rarely degraded after translation by cell's physiological processes ensuring short-term antigen expression.[10,11]

mRNA vaccines are considered safe according to clinical studies, and most adverse effects have been mild and self-resolution. That makes them more secure than live-attenuated or viral vector based vaccines.[12]

7.4 Personalized Therapy Potential

One of the most revolutionary facets of mRNA vaccines is the potential for personalized medicine. From tumor sequencing data, it is possible to synthesize a personalized vaccine based on patient-specific neoantigens that should generate point-based immune response against neoplastic cells.[13,14]

Melanoma represents one such disease with genetic heterogeneity mediating disease progression and therapeutic resistance, a personalized approach. The ability to elicit robust and durable immune responses render personalized mRNA vaccines as potential clinical outcome enhancers.[14]

8. Challenges and Limitations

Although the potential of mRNA vaccines for melanoma therapy is substantial, there are a few hurdles and barriers that still to be overcome prior to their widespread application in clinic. These range from stability and delivery to storage, safety and cost issues.[10,11]

8.1 mRNA Instability

While this type of vaccine has been a much-needed tool in the effort against COVID, one of the major issues with mRNA vaccines is their internal fragility. mRNA molecules are extremely prone to degradation by ribonucleases (RNases) that are ubiquitous in biological milieus. This instability can reduce the performance of antigen expression, which is detrimental to vaccine efficacy.[10,19]

Researchers have made efforts to overcome these limitations through various approaches, including nucleotide modifications, optimized sequence design and encapsulation in protective delivery systems. Yet, ensuring stability during manufacture, storage and in vivo delivery remains an urgent challenge.[19]

8.2 Delivery Efficiency

The successful delivery of mRNA to target cells is important for vaccination efficiency. “RNA in itself is very big, and because it has a negative charge, it can't simply penetrate through cell membranes. Although lipid nanoparticles (LNPs) have improved delivery efficiency to some extent, obstacles such as incomplete cellular uptake, endosomal entrapment and skewed transfection efficiency still exist.[11,12]

In addition, existing studies are concentrated on targeted delivery in immune cells including dendritic cells. Derivation of any body can minimize antigen expression at the site of interest and a suboptimal immune reaction.[21]

8.3 Storage Requirements

High quantity of mRNA vaccines requires stringent storage conditions to remain stable and functional. In addition, current publications describing many formulations of mRNA vaccines are dependent on ultra-cold storage temperature–which presents logistical challenges and a consequence for use in resource-limited settings.[10,30] beyond its efficacious control in a more advanced healthcare system.

Distribution is more complex, and access is limited due to cold chain limitations especially in development nation. Efforts continue to optimize thermostable formulations for storage at higher temperatures, without loss of vaccine integrity.[30]

8.4 Immune-Related Adverse Effects

The mRNA vaccines are generally well-tolerated, but can evoke immune-mediated adverse effects that are largely thought to arise from innate immune activation. These can include local inflammation, fever, fatigue and rarely overstimulation of the immune system.[10,11]

Uncontrollable activation of the aforementioned innate immune pathways can reduce mRNA translation efficiency, which can impact the vaccine efficacy. Therefore, both mRNA design and delivery systems must be thoroughly optimized to achieve the delicate balance between immunogenicity and safety.[11,23]

8.5 High Cost and Scalability

mRNA vaccines involve sophisticated advanced manufacturing processes such as in vitro transcription, purification and nanoparticle formulation which translate into a high cost of goods. Furthermore, personalized mRNA vaccines require individualized design and production, leading to higher costs.[19,23]

Scalability is another challenge, particularly with personalized therapies, because each vaccine must be designed based on the patient's tumor profile. These manufacturing and economic challenges will need resolution prior to the widespread use of mRNA vaccines as therapeutics for melanoma.[23]

9. Future Perspectives

Further research is on for current inhibition, however an area of rapid progress in mRNA-based vaccines are new inhibitors aimed at improving therapeutic efficacy. Personalized strategy and delivery technologies coupled with integrated computational biology will probably position mRNA vaccines in an even larger role for melanoma and other cancers.[10,11]

9.1 AI-Driven Neoantigen Prediction

The application of AI and machine learning for neoantigen prediction pipelines is becoming routine, enabling the faster and more accurate design or personalized mRNA vaccines. The approaches function by screening genomic data from tumors to find neoantigens that induce strong T-cell responses termed highly immunogenic.[13]

In addition, AI-based algorithms can help predict peptide–MHC binding affinity, antigen processing and the immunogenicity of genotyped patients to enhance vaccine efficacy. These technologies significantly shorten the time frame for vaccine development and enable more focused targeting at tumor-specific mutations.[31]

9.2 Combination Immunotherapies

Combination strategies with mRNA vaccines and various other immunotherapies will likely be found in future therapeutics to pursue synergy. This introduction features combinations with immune checkpoint antibodies, adoptive T-cell therapeutics and cytokine-based therapeutics that have informed strategies to enhance anti-tumor responses.[9]

Such combinations are meant to overcome immune resistance mechanisms and enhance response durability. D') Combining checkpoint blockade with mRNA vaccines, for instance, may enhance T-cell activation and reduce immune suppression in the tumor microenvironment.[9]

9.3 Improved Delivery Systems

This semi-In vivo delivery could reaching the therapeutic mRNA vaccines potential. New delivery systems (i.e. lipid nanoparticles, polymeric carriers, hybrid nanomaterials) are designed for enhanced stability, specificity and cellular desorption.[11,12]

Delivery to dendric cell specifically or improved endosomal escape mechanism would dramatically improve the efficiency of vaccine.[46-48] In addition, the development of thermostable formulations now being pursued will address existing storage and distribution challenges.[21]

9.4 Expansion to Other Cancers

The majority of mRNA vaccine research has been focused on melanoma with subsequent ongoing studies expanding their application in other major malignancies like lung cancer, breast cancer, colorectal cancer and glioblastoma.[12,13]

As a result, mRNA technology is extremely versatile and can be quickly adjusted to encode for the target tumor antigen or neoantigen in various tumor types. This broad utilization places mRNA vaccines poised to serve as a universal platform for cancer immunotherapy and may upend treatment paradigms in multiple cancers.[12]

CONCLUSION

The inducer of the immune system against the melanoma as a vaccine paved a way for mRNA-derived vaccines to emerge like paradigm-changing therapy in this position. They can carry tumor-associated antigens and synthetic neoantigens (the type of antigen presented on the surface of a transformed cell) in a size-dependent manner which potentiate strong and specific immune responses by recruiting CD8+ cytotoxic T cells, as well as CD4+ helper T cells.[10]

The speed of development, the high specificity and safety profile of mRNA vaccines compared with classical therapeutic modalities have positioned mRNA vaccines as promising candidates for therapeutic intervention. Beneficial effects were seen specifically in clinical

trials involving immune checkpoint inhibitors with or without mRNA vaccines including those that reduced disease recurrence and improved the immune response.

In the context of modern oncology, mRNA vaccines represent a potential lynchpin of precision medicine. Their ability to be customized as well as their alignment with personalized treatment strategy make them one of the flagship components of next generation cancer therapies. The definition of mRNA vaccines as polyepitope agents could greatly help with tumor heterogeneity and immune escape because they have the potential to target numerous tumor antigens at once.

Improving the clinical utility: a key tradeoff with mRNA vaccines in being able to train on data leading up to high-quality neoantigens as well as building up platforms over to combinatorial immunotherapies one option of a direct potential to improve use that can further increase them clinically. As more long-term data emerges from ongoing clinical trials, mRNA-based vaccines will increasingly fill an important niche in melanoma management and could eventually expand to treatment of other malignancies. Conclusion: The mRNA-based vaccines are promising candidates for improving patient outcomes and shaping the future of cancer immunotherapy.

REFERENCES

1. Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet., 2018; 392: 971–84.
2. Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: from pathogenesis to therapy. Int J Oncol., 2018; 52: 1071–80.
3. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma. J Invest Dermatol., 2016; 136: 1161–71.
4. Matthews NH, Li WQ, Qureshi AA, et al. Epidemiology of melanoma. In: Cutaneous Melanoma: Etiology and Therapy. Codon Publications; 2017.
5. Domingues B, Lopes JM, Soares P, et al. Melanoma treatment in review. ImmunoTargets Ther., 2018; 7: 35–49.
6. Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol., 2017; 14: 463–82.
7. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med., 2015; 372: 2521–32.

8. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab in melanoma. N Engl J Med., 2015; 373: 23–34.
9. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359: 1350–5.
10. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov., 2018; 17: 261–79.
11. Sahin U, Karikó K, Türeçi Ö. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov., 2014; 13: 759–80.
12. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today, 2019; 28: 100766.
13. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017; 547: 217–21.
14. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547: 222–6.
15. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949–54.
16. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell, 2012; 150: 251–63.
17. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med., 2018; 24: 541–50.
18. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 2017; 168: 707–23.
19. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther., 2019; 27(4): 710–28.
20. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol., 2012; 9(11): 1319–30.
21. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater, 2021; 6: 1078–94.
22. Hassett KJ, Benenato KE, Jacquinet E, et al. Optimization of lipid nanoparticles for intramuscular delivery of mRNA vaccines. Mol Ther Nucleic Acids, 2019; 15: 1–11.
23. Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Nat Rev Drug Discov., 2017; 16: 599–614.
24. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 9th ed. Elsevier; 2018.

25. Murphy K, Weaver C. Janeway's Immunobiology. 9th ed. Garland Science; 2016.
26. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes. Nat Rev Cancer, 2014; 14(2): 135–46.
27. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med., 2004; 10(9): 909–15.
28. ModernaTX Inc. Personalized cancer vaccine (mRNA-4157) clinical study data. Nat Med., 2023; 29: 1–8.
29. Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019; 565: 240–5.
30. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci., 2021; 110(3): 997–1001.
31. Chowell D, Krishna S, Becker PD, et al. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci U S A., 2015; 112(14): E1754–62.